
Find Reports
Select Report Type
Reimbursement Review
Displaying 151 - 175 of 1264
Please scroll or swipe to the right to view the full content.
Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
---|---|---|---|---|---|---|---|---|
Keytruda | pembrolizumab | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0280-000 | |||
Dupixent | dupilumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | SR0745-000 | |||
Saphnelo | anifrolumab | Systemic lupus erythematosus | Reimburse with clinical criteria and/or conditions | Complete | SR0717-000 | |||
Ferriprox | deferiprone | Transfusional iron overload | Reimburse with clinical criteria and/or conditions | Complete | SR0741-000 | |||
Benlysta | belimumab | Lupus nephritis | Reimburse with clinical criteria and/or conditions | Complete | SR0746-000 | |||
Beovu | brolucizumab | Diabetic macular edema | Reimburse with clinical criteria and/or conditions | Complete | SR0747-000 | |||
Dupixent | dupilumab | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | SF0754-000 | |||
Dayvigo | lemborexant | Insomnia | Do not reimburse | Complete | SR0716-000 | |||
Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0295-000 | |||
Nubeqa | darolutamide | Metastatic castration-sensitive prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0294-000 | |||
Kimmtrak | tebentafusp | unresectable or metastatic uveal melanoma | Reimburse with clinical criteria and/or conditions | Complete | PC0290-000 | |||
Radicava | edaravone | Amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete | SR0727-000 | |||
Zepzelca | lurbinectedin | metastatic small cell lung cancer (SCLC) | Do not reimburse | Complete | PC0281-000 | |||
Vyepti | eptinezumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | SR0743-000 | |||
Ozurdex | dexamethasone intravitreal implant | Diabetic macular edema | Do not reimburse | Complete | SR0739-000 | |||
Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete | SR0715-000 | |||
Keytruda | pembrolizumab | recurrent, or metastatic cervical cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0292-000 | |||
Tremfya | guselkumab | Psoriatic arthritis | Reimburse with clinical criteria and/or conditions | Complete | SR0733-000 | |||
Zeposia | ozanimod | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | SR0714-000 | |||
Tezspire | tezepelumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | SR0731-000 | |||
Nucala | mepolizumab | Severe chronic rhinosinusitis with nasal polyps | Reimburse with clinical criteria and/or conditions | Complete | SR0735-000 | |||
Xydalba | dalbavancin | Acute bacterial skin and skin structure infections | Reimburse with clinical criteria and/or conditions | Complete | SR0728-000 | |||
Vraylar | cariprazine | Bipolar Disorder | Do not reimburse | Complete | SR0718-000 | |||
Palynziq | pegvaliase | Phenylketonuria | Reimburse with clinical criteria and/or conditions | Complete | SR0712-000 | |||
Keytruda | pembrolizumab | Melanoma Adjuvant Treatment | Reimburse with clinical criteria and/or conditions | Complete | PC0286-000 |
Health Technology Review
Displaying 151 - 175 of 590
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 39 of 39
View All Reports
Displaying 151 - 175 of 2100
Please scroll or swipe to the right to view the full content.
Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
---|---|---|---|---|---|---|---|
inclisiran | Reimbursement Review | Complete | SR0791-001 | ||||
inclisiran | Reimbursement Review | Complete | SR0791-000 | ||||
avapritinib | Reimbursement Review | Active | PC0335-000 | ||||
Multiple Myeloma | Reimbursement Review | Provisional Funding Algorithm | Active | PH0068-000 | |||
danicopan | Reimbursement Review | Active | SR0815-000 | ||||
Brentuximab vedotin | Reimbursement Review | Complete | PC0371-000 | ||||
enfortumab vedotin | Reimbursement Review | Active | PC0353-000 | ||||
Antiviral Drugs for the Treatment of Suspected or Confirmed Influenza A or Influenza B | Health Technology Review | Systematic Review | In Progress | RE0052-000 | |||
Icatibant Implementation Advice Panel | Health Technology Review | Technology Review | Completed | HC0097-000 - SX0849-000 | |||
donanemab | Reimbursement Review | Suspended | SR0857-000 | ||||
lecanemab | Reimbursement Review | Suspended | SR0822-000 | ||||
atogepant | Reimbursement Review | Complete | SR0817-000 | ||||
Emerging Antiviral Drugs to Prevent or Treat Influenza | Horizon Scan | Emerging Health Technologies | Completed | EH0128-000 | |||
sotatercept | Reimbursement Review | Active | SR0828-000 | ||||
belumosudil | Reimbursement Review | Complete | SR0789-000 | ||||
Endometrial cancer | Reimbursement Review | Provisional Funding Algorithm | Active | PH0066-000 | |||
Philadelphia negative acute lymphoblastic leukemia | Reimbursement Review | Provisional Funding Algorithm | Active | PH0067-000 | |||
Non-small-cell lung cancer | Reimbursement Review | Provisional Funding Algorithm | Active | PH0065-000 | |||
vutrisiran | Reimbursement Review | Complete | SR0801-000 | ||||
somapacitan | Reimbursement Review | Complete | SR0779-000 | ||||
dupilumab | Reimbursement Review | Complete | SR0774-000 | ||||
roflumilast | Reimbursement Review | Complete | SR0771-000 | ||||
cenobamate | Reimbursement Review | Complete | SR0770-000 | ||||
setmelanotide | Reimbursement Review | Complete | SR0769-000 | ||||
evolocumab | Reimbursement Review | Complete | SR0821-000 |